MTVA
MetaViaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The post-earnings company materials kept the constructive operating story intact: DA-1726 Part 3 is underway, management is leaning into higher-dose titration to improve tolerability, and prior 48 mg data are being used to argue best-in-class potential in obesity and cardiometabolic disease [#8-K-2026-05-14] [#10-Q-2026-05-14].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Cash runway is guided only into Q4 2026, keeping dilution or other financing highly likely if development timelines slip [#10-Q-2026-05-14] [#10-K-2026-03-26].
Momentum
69
Value
58
Sentiment
23
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.00 · Bull $2.50 · Bear $0.40
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $19.33
Why
Momentum69 · Δ7d -
Value58 · Δ7d -0.0
Sentiment23 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
69
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.0
Sentiment
23
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 69.4 / Value 58.1 / Sentiment 23.0
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$8.16M
Beta
0.28
Shares Out
5.16M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.24
Rev YoY
-
EPS YoY
-80.0%
Gross Margin
-
Op Margin
-
Net Debt
-$10.07M
Current Ratio
2.73
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology